{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:31Z","timestamp":1787010211224,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"39","license":[{"start":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T00:00:00Z","timestamp":1727395200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,27]]},"abstract":"<jats:p>\n                    Familial hypercholesterolemia (FH) is a genetic disorder that results in elevated low-density lipoprotein cholesterol (LDL-C) levels, which manifest early in the first decades of life. It is a major cause of premature coronary artery disease worldwide, leading to significant public health challenges. The prevalence of genetically determined FH in patients with premature coronary artery disease remains underestimated, particularly in developing countries. This study aimed to assess the prevalence of genetically defined FH in Vietnamese patients with premature acute myocardial infarction (AMI) in the Vietnamese population. This cross-sectional study enrolled 218 consecutive patients diagnosed with premature AMI who underwent coronary angiography. The low-density lipoprotein receptor (\n                    <jats:italic toggle=\"yes\">LDLR<\/jats:italic>\n                    ), apolipoprotein B, and proprotein convertase subtilisin-kexin type 9 genes were analyzed by next-generation sequencing. FH was diagnosed according to Dutch Lipid Clinic Network criteria. Among the patients with premature AMI who underwent coronary angiography, the mean age was 46.9\u2005\u00b1\u20056.1 years, with a predominance of males (83.9%). The prevalence of potential FH diagnosed using Dutch Lipid Clinic Network criteria was 14.7% (definite FH, 6.0%; probable FH, 8.7%). Pathogenic or likely pathogenic variants in\n                    <jats:italic toggle=\"yes\">LDLR<\/jats:italic>\n                    , apolipoprotein B, and proprotein convertase subtilisin-kexin type 9 were found in 9 of 218 patients (4.1%), all of which were causative mutations in\n                    <jats:italic toggle=\"yes\">LDLR<\/jats:italic>\n                    . Patients with premature AMI and FH had significantly greater LDL-C levels (217.6 vs 125.7\u2009mg\/dL) and more severe coronary artery lesions, as assessed by the Gensini score (100.3 vs 60.5), than did those in the No FH group. The prevalence of genetically determined FH among Vietnamese patients with premature AMI is relatively high. Screening and diagnosis of hereditary conditions in patients with premature AMI are essential to improve early detection and management and reduce the burden of coronary artery disease in this population.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000039939","type":"journal-article","created":{"date-parts":[[2024,9,27]],"date-time":"2024-09-27T17:00:49Z","timestamp":1727456449000},"page":"e39939","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Prevalence of genetically diagnosed familial hypercholesterolemia in Vietnamese patients with premature acute myocardial infarction"],"prefix":"10.1097","volume":"103","author":[{"given":"Kha Minh","family":"Nguyen","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"Department of Cardiology, Cho Ray Hospital, Ho Chi Minh City, Vietnam."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-648X","authenticated-orcid":false,"given":"Sy Van","family":"Hoang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam"},{"name":"Department of Cardiology, Cho Ray Hospital, Ho Chi Minh City, Vietnam."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association.","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"R2-20250504","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society.","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J"},{"key":"R3-20250504","first-page":"e20","article-title":"Worldwide Prevalence of Familial Hypercholesterolemia: Meta-Analyses of 11 Million Subjects.","volume":"315","author":"Beheshti","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1016\/j.cjca.2019.06.017","article-title":"Estimating the prevalence of familial hypercholesterolemia in acute coronary syndrome: a systematic review and meta-analysis.","volume":"35","author":"Kramer","year":"2019","journal-title":"Can J Cardiol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1161\/CIRCULATIONAHA.119.044795","article-title":"Prevalence of familial hypercholesterolemia among the general population and patients with atherosclerotic cardiovascular disease: a systematic review and meta-analysis.","volume":"141","author":"Hu","year":"2020","journal-title":"Circulation"},{"key":"R6-20250504","doi-asserted-by":"crossref","first-page":"e013225","DOI":"10.1161\/JAHA.119.013225","article-title":"Diagnosis and treatment of heterozygous familial hypercholesterolemia.","volume":"8","author":"McGowan","year":"2019","journal-title":"J Am Heart Assoc"},{"key":"R7-20250504","doi-asserted-by":"crossref","first-page":"236","DOI":"10.31083\/j.rcm2408236","article-title":"Familial hypercholesterolemia: pitfalls and challenges in diagnosis and treatment.","volume":"24","author":"Arnold","year":"2023","journal-title":"Rev Cardiovasc Med"},{"key":"R8-20250504","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.atherosclerosis.2003.11.010","article-title":"Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia.","volume":"173","author":"Civeira","year":"2004","journal-title":"Atherosclerosis"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"558","DOI":"10.5551\/jat.CR005","article-title":"Guidelines for the diagnosis and treatment of adult familial hypercholesterolemia 2022.","volume":"30","author":"Harada-Shiba","year":"2023","journal-title":"J Atheroscler Thromb"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/MOL.0000000000000664","article-title":"Autosomal recessive hypercholesterolemia: update for 2020.","volume":"31","author":"D\u2019Erasmo","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel.","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"100157","DOI":"10.1016\/j.ajpc.2021.100157","article-title":"Familial hypercholesterolemia in Southeast and East Asia.","volume":"6","author":"Jackson","year":"2021","journal-title":"Am J Prevent Cardiol"},{"key":"R14-20250504","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/TACG.S202942","article-title":"High prevalence of genetic determined familial hypercholesterolemia in premature coronary artery disease.","volume":"12","author":"Pirazzi","year":"2019","journal-title":"Appl Clin Genet"},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.3390\/jcm9113489","article-title":"Familial hypercholesterolemia in premature acute coronary syndrome. Insights from CholeSTEMI Registry.","volume":"9","author":"Lorca","year":"2020","journal-title":"J Clin Med"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/j.jacc.2017.08.009","article-title":"Genetically confirmed familial hypercholesterolemia in patients with acute coronary syndrome.","volume":"70","author":"Amor-Salamanca","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.atherosclerosis.2020.05.004","article-title":"A systematic review of LDLR, PCSK9, and APOB variants in Asia.","volume":"305","author":"Mahdieh","year":"2020","journal-title":"Atherosclerosis"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/00325481.2023.2182579","article-title":"The prevalence and treatment patterns of familial hypercholesterolemia among Thai patients with premature coronary artery disease.","volume":"135","author":"Nawaka","year":"2023","journal-title":"Postgrad Med"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"e0273896","DOI":"10.1371\/journal.pone.0273896","article-title":"Familial hypercholesterolaemia and coronary risk factors among patients with angiogram-proven premature coronary artery disease in an Asian cohort.","volume":"17","author":"Nazli","year":"2022","journal-title":"PLoS One"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"914","DOI":"10.3389\/fgene.2020.00914","article-title":"Genetics, screening, and treatment of familial hypercholesterolemia: experience gained from the implementation of the Vietnam familial hypercholesterolemia registry.","volume":"11","author":"Truong","year":"2020","journal-title":"Front Genet"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.3390\/jpm13121725","article-title":"Prevalent Variants in the LDLR Gene Impair responsiveness to rosuvastatin among family members of patients with premature myocardial infarction.","volume":"13","author":"Kien","year":"2023","journal-title":"J Pers Med"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/eurheartj\/ehy462","article-title":"Fourth universal definition of myocardial infarction (2018).","volume":"40","author":"Thygesen","year":"2019","journal-title":"Eur Heart J"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"121","DOI":"10.7570\/jomes23031","article-title":"Diagnosis of Obesity: 2022 update of clinical practice guidelines for obesity by the Korean Society for the Study of Obesity.","volume":"32","author":"Haam","year":"2023","journal-title":"J Obesity Metab Syndrome"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S0002-9149(83)80105-2","article-title":"A more meaningful scoring system for determining the severity of coronary heart disease.","volume":"51","author":"Gensini","year":"1983","journal-title":"Am J Cardiol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.atherosclerosis.2015.03.003","article-title":"Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.","volume":"240","author":"Haralambos","year":"2015","journal-title":"Atherosclerosis"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.atherosclerosis.2015.04.809","article-title":"Prevalence and management of familial hypercholesterolaemia in coronary patients: an analysis of EUROASPIRE IV, a study of the European Society of Cardiology.","volume":"241","author":"De Backer","year":"2015","journal-title":"Atherosclerosis"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology.","volume":"17","author":"Richards","year":"2015","journal-title":"Genet Med"},{"key":"R28-20250504","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ihj.2018.12.004","article-title":"Prevalence of familial hypercholesterolemia in premature coronary artery disease patients admitted to a tertiary care hospital in North India.","volume":"71","author":"Sawhney","year":"2019","journal-title":"Indian Heart J"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.23154","article-title":"Prevalence of familial hypercholesterolemia in patients with premature myocardial infarction.","volume":"42","author":"Cui","year":"2019","journal-title":"Clin Cardiol"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11886-021-01540-0","article-title":"Monogenic and polygenic models of coronary artery disease.","volume":"23","author":"Muse","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"16942","DOI":"10.1038\/s41598-023-44065-y","article-title":"Prevalence and prognosis of genetically proven familial hypercholesterolemia in subjects with coronary artery disease and reduced ejection fraction.","volume":"13","author":"Lee","year":"2023","journal-title":"Sci Rep"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.3390\/biomedicines10102639","article-title":"Familial hypercholesterolaemia as a predisposing factor for atherosclerosis.","volume":"10","author":"Poznyak","year":"2022","journal-title":"Biomedicines"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s43044-022-00320-7","article-title":"Prevalence of familial hypercholesterolemia in patients with confirmed premature coronary artery disease in Ranchi, Jharkhand.","volume":"74","author":"Kumar","year":"2022","journal-title":"Egypt Heart J"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1016\/j.jacl.2016.06.002","article-title":"Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation.","volume":"10","author":"Mortensen","year":"2016","journal-title":"J Clin Lipidol"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.jacc.2020.07.059","article-title":"Time Course of LDL Cholesterol Exposure and Cardiovascular Disease Event Risk.","volume":"76","author":"Domanski","year":"2020","journal-title":"J Am Coll Cardiol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039939","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T20:45:48Z","timestamp":1746305148000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000039939"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,27]]},"references-count":35,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000039939","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,27]]}}}